1744-22-5Relevant articles and documents
DNA-binding, -cleavage and antimicrobial investigation on mononuclear Cu(II) Schiff base complexes originated from Riluzole
Daravath, Sreenu,Rambabu, Aveli,Shankar, Dasari Shiva,Shivaraj
, (2021)
Two mononuclear metal complexes, [Cu(L1)2] (1) and [Cu(L2)2] (2) of the respective Schiff bases, HL1 = 2-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)-4-methoxyphenol and HL2 = 2-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)-4,6-dibromophenol were synthesized and well characterized by analytical and various spectroscopic techniques like elemental analysis, NMR, mass spectrometry, IR, UV, ESR and thermogravimetric analyses. These spectral studies gave a square planar geometry for both the complexes. These complexes underwent DNA investigation against calf thymus DNA and supercoiled pBR322 DNA. The complexes bound the DNA through an intercalation mode and the binding affinity order follows as 1 > 2 > HL2 > HL1. Both complexes show good cleavage ability against double-stranded pBR322 DNA under oxidative and photolytic conditions. In vitro antimicrobial study resulted in both complexes have shown marked biocidal potential compared to respective free ligands.
DNA interaction, antimicrobial studies of newly synthesized copper (II) complexes with 2-amino-6-(trifluoromethoxy)benzothiazole Schiff base ligands
Rambabu, Aveli,Pradeep Kumar, Marri,Tejaswi, Somapangu,Vamsikrishna, Narendrula,Shivaraj
, (2016)
Four novel Schiff base ligands, L1 (1-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)naphthalen-2-ol, C19H11F3N2O2S), L2 (3-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)benzene-1,2-diol, C15H9F3N2O3S), L3 (2-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)-5-methoxyphenol, C16H11F3N2O3S) and L4 (2-((E)-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylimino)methyl)-4-bromophenol, C15H8BrF3N2O2S) and their binary copper(II) complexes 1 [Cu(L1)2], 2 [Cu(L2)2], 3 [Cu(L3)2] and 4 [Cu(L4)2] have been synthesized and characterized by elemental analysis, 1H NMR, 13C NMR, ESI mass, FT-IR, ESR, UV–Visible, magnetic susceptibility, TGA, SEM and powder XRD studies. Based on spectral and analytical data, a square planar geometry is assigned for all Cu(II) complexes. The ligands and their Cu(II) complexes have been screened for antimicrobial activity against bacterial species E. coli, P. aeruginosa, B. amyloliquefaciens and S. aureus and fungal species S. rolfsii and M. phaseolina and it is observed that all Cu(II) complexes are more potent than corresponding ligands. DNA binding (UV absorption, fluorescence and viscosity titrations) and cleavage (oxidative and photo cleavage) studies of Cu(II) complexes have also been investigated against calf thymus DNA (CT-DNA) and supercoiled pBR322 DNA respectively. From the experimental results, it is found that the complexes bound effectively to CT-DNA through an intercalative mode and also cleaved pBR322 DNA in an efficient manner. The DNA binding and cleavage affinities of newly synthesized Cu(II) complexes are in the order of 2 > 1 > 3 > 4.
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and in Vitro and in Vivo Investigations
Mishra, Chandra Bhushan,Kumari, Shikha,Angeli, Andrea,Bua, Silvia,Mongre, Raj Kumar,Tiwari, Manisha,Supuran, Claudiu T.
, p. 3100 - 3114 (2021/04/12)
Two sets of benzenesulfonamide-based effective human carbonic anhydrase (hCA) inhibitors have been developed using the tail approach. The inhibitory action of these novel molecules was examined against four isoforms: HCA I, hCA II, hCA VII, and hCA XII. Most of the molecules disclosed low to medium nanomolar range inhibition against all tested isoforms. Some of the synthesized derivatives selectively inhibited the epilepsy-involved isoforms hCA II and hCA VII, showing low nanomolar affinity. The anticonvulsant activity of selected sulfonamides was assessed using the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole (sc-PTZ) in vivo models of epilepsy. These potent CA inhibitors effectively inhibited seizures in both epilepsy models. The most effective compounds showed long duration of action and abolished MES-induced seizures up to 6 h after drug administration. These sulfonamides were found to be orally active anticonvulsants, being nontoxic in neuronal cell lines and in animal models.
Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series
Fleau, Charlotte,Padilla, Angel,Miguel-Siles, Juan,Quesada-Campos, Maria T.,Saiz-Nicolas, Isabel,Cotillo, Ignacio,Cantizani Perez, Juan,Tarleton, Rick L.,Marco, Maria,Courtemanche, Gilles
, p. 10362 - 10375 (2019/11/29)
Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure-activity relationship, allowing optimization of antiparasite activity, physicochemical parameters, and ADME properties. We identified compound 50 as an advanced lead with an improved anti-T. cruzi activity in vitro (IC50 = 0.079 μM) and an enhanced metabolic stability (human clearance = 0.41 mL/min/g) and opportunity for the oral route of administration. After tolerability assessment, 50 demonstrated a promising in vivo efficacy.
